What is an appropriate treatment plan for a 45-year-old male with a history of hypertension, elevated triglycerides, and elevated total cholesterol?

Treatment Plan for 45-Year-Old Male with Hypertension, Triglycerides 425 mg/dL, and Total Cholesterol 236 mg/dL

This patient requires immediate initiation of moderate-to-high intensity statin therapy combined with aggressive lifestyle modifications to address his moderate hypertriglyceridemia and elevated cardiovascular risk. 1

Risk Stratification and Treatment Goals

This 45-year-old male with hypertension and dyslipidemia falls into a moderate-to-high cardiovascular risk category. His triglycerides of 425 mg/dL classify him as having moderate hypertriglyceridemia (175-499 mg/dL), which is associated with increased atherosclerotic cardiovascular disease (ASCVD) risk. 1

Target lipid goals:

• LDL-cholesterol: <100 mg/dL (calculate from lipid panel: LDL = Total cholesterol - HDL - [Triglycerides/5]) 1
• Non-HDL-cholesterol: <130 mg/dL (Total cholesterol - HDL) 1
• Triglycerides: <150 mg/dL 1
• Blood pressure: <130/80 mmHg 1

Immediate Pharmacologic Therapy

Statin Therapy (First-Line)

Initiate moderate-to-high intensity statin therapy immediately. For a 45-year-old with hypertension and moderate hypertriglyceridemia, start with: 1

• Atorvastatin 40 mg daily (high-intensity, lowers LDL-C by >50% and provides moderate triglyceride reduction of 20-30%), OR 1
• Rosuvastatin 20 mg daily (high-intensity alternative) 1

The 2023 ADA guidelines recommend high-intensity statin therapy for adults aged 40-75 with additional ASCVD risk factors (hypertension qualifies), targeting LDL-C reduction ≥50% and LDL-C goal <70 mg/dL. 1 Higher-dose statins are moderately effective at reducing triglycerides in patients with levels <500 mg/dL. 1

Hypertension Management

Continue or optimize blood pressure control with beta-blockers and/or ACE inhibitors as first-line agents, adding thiazides as needed to achieve target <130/80 mmHg. 1

Aggressive Lifestyle Modifications (Mandatory)

Address secondary causes and lifestyle factors immediately—these are critical for triglyceride reduction: 1

Dietary Interventions

• Reduce saturated fat to <7% of total calories 1
• Eliminate trans-fatty acids completely 1
• Restrict cholesterol intake to <200 mg/day 1
• Severely restrict refined carbohydrates and simple sugars (major triglyceride driver) 1
• Eliminate or drastically reduce alcohol consumption (alcohol significantly raises triglycerides) 1
• Adopt Mediterranean or DASH diet pattern 1
• Add plant stanols/sterols (2 g/day) and viscous fiber (≥10 g/day) for additional LDL-C lowering 1

Physical Activity

• 30-60 minutes of moderate-intensity aerobic activity daily (minimum 5 days/week, preferably 7 days) 1
• Resistance training 2 days per week 1

Weight Management

• Target BMI 20-25 kg/m² 1
• Waist circumference <94 cm 1
• Weight loss is particularly effective for triglyceride reduction in patients with metabolic syndrome 1

Omega-3 Fatty Acids

• Consume fatty fish 2-3 times weekly OR omega-3 supplements 1-4 g/day for additional triglyceride lowering 1

Secondary Causes to Evaluate

Rule out secondary causes of hypertriglyceridemia: 1, 2

• Diabetes mellitus or prediabetes (check HbA1c, fasting glucose)
• Hypothyroidism (check TSH)
• Chronic kidney disease (check creatinine, eGFR)
• Chronic liver disease (check liver function tests)
• Medications that raise triglycerides: thiazide diuretics (if used for HTN), beta-blockers, oral estrogens, glucocorticoids, atypical antipsychotics, protease inhibitors 1

Follow-Up and Monitoring

Recheck fasting lipid panel in 4-12 weeks after statin initiation: 1

• If LDL-C remains >100 mg/dL or triglycerides remain >200 mg/dL despite maximal lifestyle changes and statin therapy, consider intensifying therapy 1

Consideration for Additional Therapy

If Triglycerides Remain Elevated (>200 mg/dL) After 3 Months

Consider adding fibrate therapy or high-dose omega-3 fatty acids (icosapent ethyl 4 g/day) if: 1

• Triglycerides remain 200-499 mg/dL on maximally tolerated statin therapy
• Patient has achieved optimal lifestyle modifications
• ASCVD risk remains elevated (≥7.5% 10-year risk)

Fenofibrate is preferred over gemfibrozil when combining with statins due to lower risk of rhabdomyolysis. 1 However, combination therapy increases risk of muscle toxicity and requires close monitoring. 1

The 2021 ACC Expert Consensus supports icosapent ethyl (purified EPA) 2 g twice daily for patients with triglycerides 150-499 mg/dL on statin therapy with established ASCVD or diabetes plus additional risk factors, based on REDUCE-IT trial results showing significant cardiovascular benefit. 1, 3

Critical Pitfalls to Avoid

• Do not delay statin therapy while attempting lifestyle modifications alone—start both simultaneously 1
• Do not use gemfibrozil with statins due to high rhabdomyolysis risk; fenofibrate is safer if combination needed 1
• Do not ignore alcohol intake—even moderate consumption significantly elevates triglycerides 1
• Do not overlook undiagnosed diabetes—hyperglycemia is a major contributor to hypertriglyceridemia 1
• Monitor for statin-associated muscle symptoms but recognize they are uncommon and manageable 1

Summary Algorithm

1. Immediate: Start atorvastatin 40 mg or rosuvastatin 20 mg daily 1
2. Immediate: Implement comprehensive lifestyle modifications (diet, exercise, weight loss, alcohol restriction) 1
3. Immediate: Optimize blood pressure control 1
4. Within 1-2 weeks: Screen for secondary causes (diabetes, hypothyroidism, kidney/liver disease) 1
5. 4-12 weeks: Recheck fasting lipids and assess response 1
6. If inadequate response at 3 months: Consider adding fenofibrate or icosapent ethyl 1